All articles tagged with #medicare advantage
CMS approved a 2.48% funding uplift for 2027, adding over $13 billion to Medicare Advantage plans and giving insurers more room to hold premiums and maintain extra benefits like dental and vision; while overall health-care costs won't drop dramatically, the change could ease out-of-pocket costs for many seniors, making coverage more stable—so review plans during open enrollment.
Aetna will pay $117.7 million to settle False Claims Act allegations that it submitted or failed to withdraw inaccurate diagnosis codes to inflate Medicare Advantage payments, including morbid obesity codes for 2018–2023, and related issues from a 2015 chart-review program; a whistleblower, a former Aetna risk-adjustment coder, will receive about $2.01 million. The case was pursued by the DOJ Civil Division, Fraud Section, and HHS-OIG with the U.S. Attorney’s Office for the Eastern District of Pennsylvania.
The Trump administration proposes a 2027 pay increase for Medicare Advantage of less than 1% (about $700 million), a smaller boost than insurers hoped and aimed at stabilizing payments while curbing upcoding. Insurers warn the modest increase could force benefit cuts or higher seniors’ premiums, while CMS argues the measure is a right-sizing effort to reduce waste; a final rate decision in spring will trigger renewed lobbying from industry and policymakers.
UnitedHealth Group dropped about 20% after it forecast a at-least-2% revenue decline for 2026 and issued a subdued earnings outlook (EPS at least $17.75, medical-care ratio ~88.8%), while a smaller-than-expected Medicare Advantage rate increase and ongoing investigations added to investor concern.
UnitedHealth Group remains a contrarian buy after a selloff driven by Medicare Advantage margin concerns; 2026 revenue is expected to fall about 2% while operating income tops $24 billion due to cost controls and AI-led efficiency gains. Near-term EPS growth is about 8.6%, but management targets a long-term adjusted EPS CAGR of 13–16%, suggesting meaningful upside if multiple expands to a forward P/E around 15.8. With strong cash flow funding dividends, buybacks, and roughly $1.5 billion a year in tech/AI investments, the key risks are medical cost volatility and ongoing Medicare funding pressures.
The CMS proposed only a 0.09% average 2027 increase for Medicare Advantage rates, far below analysts’ expectations, sending shares of UnitedHealth, Humana, CVS Health and peers down sharply (as much as about 20% for UNH) on concerns about margins and future revenue. The notice also highlighted a plan to exclude diagnosis information from certain risk-score calculations, which could further affect payments. Analysts noted the flat-rate stance would blunt the sector’s margin turnaround despite past rate hikes, contributing to a broad market pullback in health-insurer stocks.
UnitedHealth reported a Q4 revenue and EPS miss with its medical care ratio at 89.1%, signaling ongoing margin pressure. Medicare Advantage reimbursement increases are expected to be modest, adding near-term headwinds and tempering the earnings outlook. Management suggests 2026 will be a transition year, offering potential long-term upside for patient investors while the near term remains challenging.
Futures for the S&P 500 were largely unchanged as traders await the Fed’s rate decision this week; after Monday’s gains led by tech, health insurers fell in after-hours trading on CMS’s near-flat Medicare Advantage payment proposal for 2027, while President Trump signaled higher tariffs on South Korean autos, pharmaceuticals and lumber, adding risk to an earnings-heavy week.
Bernstein analyst Lance Wilkes designates UnitedHealth Group (UNH) as his top healthcare stock for 2026, keeping an Outperform rating with a $444 target as margins in Medicare Advantage/Medicaid are expected to recover. He expects earnings growth to resume as UNH exits unprofitable businesses and weighs the potential separation of UnitedHealthcare and Optum, with Optum viewed as a long‑term growth driver. Bernstein sees roughly 33% upside from current levels, while the broader market consensus remains bullish with a target near $398 (~19% upside).
The Justice Department announced a $556 million settlement with Kaiser Permanente over allegations that it inflated Medicare Advantage payments by adding improper diagnoses to patient charts after visits, a practice the government says diverted about $1 billion from taxpayers between 2009 and 2018; Kaiser says the settlement resolves the matter without admitting wrongdoing and notes it concerns risk-adjustment practices rather than care quality.
Kaiser Permanente agreed to pay $556 million to settle civil lawsuits accusing it of inflating patient illness levels to boost Medicare Advantage payments; the DOJ and whistleblowers alleged up to $1 billion in overbilling, with the deal setting a record Medicare Advantage settlement.
A Senate majority staff report based on more than 50,000 pages alleges UnitedHealth Group uses aggressive diagnosis capture, in-home health risk assessments, and coding guidance to inflate Medicare Advantage risk scores and in turn receive higher CMS payments. The findings describe a specialized workforce and data capabilities that adapt to CMS crackdowns, with examples like diagnoses for opioid dependence, alcohol use disorders, and dementia, and warn that the company sells its criteria to other MAOs, potentially impacting taxpayers and the integrity of the MA program. The report follows Grassley’s long history of MA oversight and calls for continued scrutiny of risk-adjustment practices.
Starting in 2026, Medicare Advantage plans will no longer cover certain items due to new CMS restrictions, marking a change from the expanded coverage seen in 2018.
Dave Ramsey emphasizes that the Medicare Annual Enrollment Period (AEP) is for current beneficiaries to modify their coverage, not for first-time enrollees, who should sign up at age 65. He explains the differences between Original Medicare and Medicare Advantage, and highlights upcoming changes in 2026, including a cap on out-of-pocket drug costs at $2,100.
UnitedHealth Group's stock rose over 4% after a better-than-expected quarterly earnings report, driven by improved medical loss ratios and cautious optimism about future growth, despite industry challenges like rising medical costs and regulatory changes.